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Aldehyde dehydrogenases engage in many cellular functions, however their dysfunction
resulting in accumulation of their substrates can be cytotoxic. ALDHs are responsible for
the NAD(P)-dependent oxidation of aldehydes to carboxylic acids, participating in
detoxification, biosynthesis, antioxidant and regulatory functions. Severe diseases,
including alcohol intolerance, cancer, cardiovascular and neurological diseases, were
linked to dysfunctional ALDH enzymes, relating back to key enzyme structure. An in-depth
understanding of the ALDH structure-function relationship and mechanism of action is key
to the understanding of associated diseases. Principal structural features 1) cofactor
binding domain, 2) active site and 3) oligomerization mechanism proved critical in
maintaining ALDH normal activity. Emerging research based on the combination of
structural, functional and biophysical studies of bacterial and eukaryotic ALDHs
contributed to the appreciation of diversity within the superfamily. Herewith, we
discuss these studies and provide our interpretation for a global understanding of
ALDH structure and its purpose–including correct function and role in disease. Our
analysis provides a synopsis of a common structure-function relationship to bridge the
gap between the highly studied human ALDHs and lesser so prokaryotic models.
Keywords: aldehyde dehydrogenase, NAD(P) cofactor, structure-function, mutations, enzyme dysfunction,
oligomerization, C-terminal extensions, spirosomes
INTRODUCTION
Aldehyde dehydrogenases (ALDH) (EC 1.2.1.3) are a family of nicotinamide adenine dinucleotide
(phosphate) (NAD(P)) dependent enzymes, typically with a molecular mass of ca. 50–60 kDa. They
oxidise a large range of aliphatic and aromatic, endogenous and exogenous aldehydes to form the
corresponding carboxylic acids. They differ in their subcellular location, tissue distribution and
preferred substrates while contributing to a broad spectrum of associated biological activities across
prokaryotes, eukaryotes and Archaea. ALDHs are involved in detoxification, biosynthesis,
antioxidant functions and structural and regulatory mechanisms (Vasiliou and Nebert, 2005).
Interestingly, some if not most, ALDHs have multiple functionality. For example, human ALDH1A1,
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possessing nitrate reductase activity Sydow et al. (2004),
suggesting more than one catalytic function of the ALDH family.
Unlike many other systems, ALDH investigation originated in
humanmodels, rather than bacterial ones which likely arises from
their central link with pathological conditions. To date 10 out of
the 19 human ALDHs have a resolved structure. Initially this led
to misconceptions and a rather inaccurate description of typical
features related to the enzyme family (Rodríguez-Zavala et al.,
2006; Hayes et al., 2018). Emerging research allows for an
accurate understanding of diversity within the ALDH family,
across prokaryotes and eukaryotes, while bridging the gap to form
a global perception of the superfamily. In addition, new enzyme
structures demonstrating novel characteristics, provides scope for
an updated, complete summary of the ALDH family structure
to date.
ALDHs are generally grouped according to sequence
identity, phylogeny and structural features combined, with
the system evolving through identification of new
superfamily members over time. Initial classification of
ALDHs commenced in the late 1980s when only few ALDH
sequences were available and which led to their classification
into 3 distinct classes: ALDH 1, 2 and 3 Lindahl and Hempel
(1990), Lindahl (1992), generally composed of human or
mammalian isozymes. Classes 1 and 3 consist of both
constitutively expressed and inducible cytosolic enzymes,
with class 3 being expressed specifically in tumor, stomach
and corneal cells. Class 2, contains constitutive mitochondrial
enzymes. Each class oxidises a variety of substrates that can be
derived from either an endogenous or exogenic source,
including aldehydes derived from xenobiotic metabolism
(Lindahl, 1992). Class 1 and 2 ALDHs contain mostly
substrate variable enzymes while class 3 contains substrate
specific ones (Perozich et al., 1999b). Generalisation with
regards to the different classes has proposed that class 1 and
2 members, usually homotetramers, contain 500 amino acids
per monomer with 70% sequence identity. Class 3 members, on
the other hand, contain 450 amino acids, harboring an
N-terminal deletion, and are of homodimeric nature
(Rodríguez-Zavala et al., 2006). The sequence identity of
class 3 in relation to class 1 or class 2 is only 25% (Perozich
et al., 1999a). With a growing number of ALDH sequences, a
new classification based on Dayhoff’s work Dayhoff (1976) was
adopted later in 1999 to establish rules for ALDH nomenclature.
Proteins with sequence identity greater than 40% were
considered to belong to the same class, while proteins with
more than 60% sequence identity have been assigned to the
same sub-class (Vasiliou et al., 1999). ALDH nomenclature now
spans from ALDH1 to ALDH24 across organisms (Brocker
et al., 2013; Hou and Bartels, 2015). Supporting this, the
human ALDH family consists of 19 putatively functional
genes encoded on distinct chromosomal locations. However,
emerging research demonstrates that significantly more ALDH
classes exist. A recent study on the Pseudomonas genus
identified 42 different classes of ALDHs demonstrating the
scope of this enzyme’s diversity, but housed in a general,
common structure (Riveros-Rosas et al., 2019).
GENERAL STRUCTURE
Introduction to the Aldehyde
Dehydrogenase Common Architecture
ALDH enzymes typically exist and function as homotetramers or
homodimers (Figures 1A,B) formed by subunits of
approximately 450–500 amino acids to construct a 50–60 kDa
protomer. The overall structure consists of three distinct,
conserved domains, the NAD(P) binding domain, the catalytic
domain and the “arm-like” oligomerization domain Liu et al.
(1997) establishing a domain fingerprint for this superfamily
(Figure 1C). At the interface of these domains, buried within the
enzyme, is a funnel-shaped cavity with an opening leading to the
catalytic pocket. Which within harbors the important catalytic
thiol, Cys residue.
The Active Site
The active site of the ALDH is located at the base of a
hydrophobic, funnel shaped tunnel, close to the subunit’s
interface and opposite the cofactor binding site. A highly
reactive active-site cysteine residue (Cys302 in ALDH1a1 and
ALDH2, Cys243 in ALDH3a1, human numbering), which is
highly conserved throughout the ALDH family, has been
accepted as the catalytic thiol (Farres et al., 1995). The side
chain of the Cys residue protrudes into the catalytic tunnel that
extends through each subunit. The upper portion of the funnel
between the catalytic Cys and the entrance, is made up of
residues from all three domains. Furthermore, this passage is
identified as a catalytic pocket, relating to where the aldehyde
first forms a tetrahedral intermediate with a Cys residue to
initiate catalysis. In addition to aldehyde oxidation, some
ALDHs possess NAD esterase activity (Feldman and Weiner,
1972; Sládek, 2003; Vasiliou and Nebert, 2005). Interestingly
these enzymes utilise the same active site residues to carry out
this function as dehydrogenase catalysis, however esterase
activity does not require the addition of the NAD(P) cofactor
(Koppaka et al., 2012). The so-called “pseudoenzyme” human
ALDH16 lacks this catalytic Cys residue, resulting in absence of
catalytic activity, proposed to function as a binding protein (Liu
and Tanner, 2019).
Conserved residues are present across the sequences of the
ALDH members, highlighting vital, positional requirements for
systematic catalysis by the enzyme. Sequence alignment of 145
known ALDHs demonstrated 4 invariant residues and 12 highly
conserved residues (present in 95% of sequences analyzed). Of
these, glycines and prolines were abundant (7 and 2, respectively),
likely highlighting critical chain-bending points due to the anti-
helical and beta-sheet potentials of these residues (Perozich et al.,
1999b). The catalytic Cys is conserved in all structures which
harbor catalytic activity, the above mentioned ALDH16 being a
prime example of a non-catalytic member (Liu and Tanner,
2019). In addition, two other important conserved residues
associated with catalysis, lysine (Lys192) and glutamic acid
(Glu268) (human numbering), are evident across the ALDHs.
Glu268 is directly involved in catalysis providing a water
molecule required for deprotonation of the catalytic thiol and
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subsequent hydrolysis of the thioester intermediate (see details at
the end of the section). Glu399 is also highly conserved and is
involved in NAD binding along with Lys192, however, Glu399 is
not as critical as Lys192, because during catalysis it is bound to the
nicotinamide ring which appears to have to move during the
catalytic process (discussed further below). An amino acid
exchange of Lys192 causes an alteration in NAD binding and
the rate-limiting step but substitution of Glu399 only alters the
latter (Sheikh et al., 1997).
Contrasts in ALDH enzymes exist within the cavity used for
entry of the substrate into the active site, called the substrate entry
channel (SEC) (Sobreira et al., 2011). The size and shape of the
SEC dictates the ability of the ALDH to process small or large
aldehydes (Figure 2). Typically, ALDH1 has a larger SEC volume
than ALDH2 (589 ± 59 and 403 ± 53 Å3, respectively), consistent
with their favored substrate. Human ALDH2 displays a narrow
channel with a constricted entrance Steinmetz et al. (1997), one of
its main substrates being acetaldehyde. In contrast sheep
FIGURE 1 | ALDH architecture (A) Homodimeric structure of the human ALDH3A1 (PDB: 3SZA). (B) Homotetrameric structure of the human mitochondrial ALDH
(PDB: 1NZX). (C) Three conserved domains illustrated on an ALDH monomer. The functional domains are highlighted: catalytic domain (blue), NAD(P) binding domain
(purple), and oligomerization domain (green).
FIGURE 2 | Substrate entry channel (SEC) of ALDH. Surface representation of the SEC of (A) ALDH2 (PDB: 3N80) showing a narrow channel suitable for small
aldehydes and (B) of the larger SEC of ALDH1A3 (PDB 5FHZ) with retinoic acid. SEC signature residues are shown in sticks. For clarity, residues 436–456 (ALDH2) and
437–466 (ALDH1A3) are not shown.
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ALDH1A1 exhibits a large SEC equipped with a broad opening
enabling access for larger aldehydes (Moore et al., 1998). This
highlights that SEC topology influences substrate preferences
within the ALDH family. ALDH2, with acetaldehyde as its
natural substrate, displays no activity for retinaldehyde, while
ALDH1 can oxidise retinaldehyde but can only inefficiently
process acetaldehyde (Klyosov, 1996; Moore et al., 1998).
Three key signature residues present in the SEC are
responsible for geometry/function and thus substrate
specificity. These residues are designated the “mouth” (124),
“neck” (459) and “bottom” (303) (human ALDH2 numbering)
(Figure 2) (Moore et al., 1998; Sobreira et al., 2011). The “mouth”
residue performs a size selection function, bovine ALDH2
possesses a bulky Met and sheep ALDH1A1 and human
ALDH1A3 a Gly (Moore et al., 1998)(Steinmetz et al., 1997;
Moretti et al., 2016), resulting in either an open or narrow
entrance to the SEC. The “neck” residue is present at the
proximal third of the channel. In vertebrate ALDH2 this
residue is a large Phe in contrast to ALDH1 where it is
typically a smaller Val or Leu (Sobreira et al., 2011)(Moretti
et al., 2016). The third signature, the “bottom”, is located directly
beside the catalytic Cys at the end of the channel. In vertebrate
ALDH2s this residue is usually a Cys, whereas in ALDH1 it can be
Thr, Ile or Val (Sobreira et al., 2011; Moretti et al., 2016). Within
ALDH2 the “neck” and “bottom” residues (Phe459 and Cys303)
assist in holding the smaller aldehyde substrate close to the
catalytic Cys–a mechanism not required for the larger
substrates in ALDH1. Favourable surface interactions between
Cys303 (“bottom”) and Phe459 (“neck”), fixates the position of
the “neck” residue and in turn the position of Phe465 which is
responsible for holding the substrate close to the catalytic thiol.
This mechanism is not present in ALDH1 due to the residues
substitutions as highlighted above, further emphasising the
specialisation of the SEC for preferred substrates (Sobreira
et al., 2011). This highlights that the size of the key amino
acid signatures dictate substrate specificity while also playing a
key role in surface interactions for further SEC specialization.
Interestingly it was demonstrated that metazoan class 1 and class
2 ALDHs are members of a single clade, with ALDH2 forming a
subgroup nested within this ALDH1/2 clade. Throughout
evolution, class 1 and 2 often switched between small and
large SECs following gene duplication, transforming restricted
small channels into wider ones and vice versa. Expansion of the
channel occurred due to substitution of a bulky methionine
residue with a small alanine or glycine, reducing steric
hindrance effects (Sobreira et al., 2011).
The electrostatic potential of the SEC plays a significant role in
dictating the range of substrates which can be utilised for
oxidation. The binding site and channel are tailored,
optimising the processing of certain aldehyde substrates.
ALDHs that bind positive substrates, commonly display a
negative electrostatic potential in the SEC and vice versa. In
contrast, ALDHs that have non-polar substrates contain neutral
electrostatic potential surfaces for easy, efficient conversion
(Riveros-Rosas et al., 2013). For example, human ALDH1,
with a physiological substrate, retinaldehyde, has a neutral
SEC (Riveros-Rosas et al., 2013; Moretti et al., 2016). ALDHs
who use positive betaine aldehydes as their substrates e.g.,
ALDH9 from Pseudomonas eruginosa (PDB: 2WME) and
ALDH25 from Staphylococcus aureus (PDB: 4MPB) are
equipped with negatively charged SECs (González-Segura
et al., 2009; Riveros-Rosas et al., 2013; C. Chen et al., 2014).
In addition, ALDH11 from Streptococcus mutans (PDB: 1EUH)
uses glyceraldehyde-3-phosphate as its substrate and displays a
positive electrostatic potential at the SEC (D’Ambrosio et al.,
2006). In contrast human ALDH3 (PDB: 3SZB), demonstrating a
negatively charged SEC is known to convert medium to long
chain aliphatic and aromatic aldehydes raising the question of the
possibility of an unidentified positively charged substrate for this
enzyme (Muzio et al., 2012; Riveros-Rosas et al., 2013).
Systematic catalysis performed by an ALDH occurs in five
distinct steps within the active site, 1) activation of the catalytic
thiol, Cys302 or equivalent, using a water molecule for water-
mediated deprotonation by Glu268, 2) consequential
nucleophilic attack on the electrophilic aldehyde by the thiol
group of the catalytic cysteine, 3) formation of a tetrahedral
thiohemiacetal intermediate, via deacylation, coupled with
concomitant hydride transfer to the pyridine ring of NAD(P),
4) hydrolysis of the resulting thioester, 5) dissociation of the
reduced cofactor producing NAD(P)H and regeneration of the
enzyme by NAD(P) binding (Figure 3). It is proposed that an
ordered water molecule plays an essential role in facilitating
catalysis. This water molecule is required to be bound to the
side chain of Glu268 to allow for both the deprotonation of the
catalytic thiol and subsequent hydrolysis of the thioester
intermediate (steps one and four highlighted above) (Koppaka
et al., 2012).
NAD(P) Cofactor Choice and Utilisation
A selection of enzymes use dinucleotide cofactors, such as NAD
or flavin adenine dinucleotide (FAD), and even though their
overall enzyme structures may differ they are normally equipped
with dinucleotide binding domains consisting of either a
Rossmann fold (Rossmann et al., 1974; Wierenga et al., 1986)
or a (α/β)8 barrel structure (Wilson et al., 1992; Hoog et al., 1994).
The cofactor-binding domain in ALDH is composed of a
Rossmann fold. The pyrophosphate moiety of the cofactor
makes close contact with the first β-α-β-α-β of the Rossmann
fold, specifically the loop between β1 and αA (Figure 4A). The
helix αA has been termed the “dinucleotide binding helix” (Hol
et al., 1978) due to the helix dipole providing a favourable
interaction with the negatively charged pyrophosphate moiety
of the dinucleotide molecule (Liu et al., 1997).
In NAD binding, binding of the adenine part of the cofactor is
conserved across ALDHs in a fixed conformation, with no
movement necessary during catalysis. In contrast, the
nicotinamide portion appears to be flexible, contributing to
variable conformations throughout superfamily members
(Figure 4B). Movement of the nicotinamide in and out of the
active site during catalysis is a conserved and important
mechanism of functional ALDHs. The adenine ring of the
NAD(P) molecule during binding resides in a hydrophobic
pocket between the helices, αF and αG, as observed in
structures of sheep ALDH1, bovine ALDH2 and rat ALDH3
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(Liu et al., 1997; Steinmetz et al., 1997; Moore et al., 1998).
Stabilisation of the adenine ring within the enzyme is conferred
by cradling of the ring using residue sidechains and hydrogen
bonds. In both ALDH1 and ALDH2 structures the adenine ribose
forms hydrogen bonds with Lys192, Glu195 and Ile166. The
specific amino acid sequence, G1XG2XXG3, which reflects the
turn at the end of the first β-strand, interacts with the adenine
ribose of the NAD molecule (Wierenga and Hol, 1983; Hempel
et al., 1993). The nicotinamide portion of the cofactor seemingly
demonstrates discrete disorder during binding leading to a
number of cofactor conformations. In contrast to bovine
ALDH2 and rat ALDH3 the nicotinamide ring binding in
sheep ALDH1 was different (Moore et al., 1998). Two major
conformations of the nicotinamide half were observed however
with the less occupied conformation mimicking bovine ALDH2
structure. The specific differences between the ALDH1 and
ALDH2 are realised, the nicotinamide ring of ALDH1
occupies nearly the same position as the nicotinamide ribose
in ALDH2, a shift of over 5 Å (Figure 4B). In addition, the same
amino acids, Gln349, Glu399 and Phe401, confer the
nicotinamide portion stabilisation in both ALDH1 and
ALDH2 however they do so in a very different manner.
Flexibility of the nicotinamide is also assisted by the
intentionally weak binding of the pyrophosphate moiety in
ALDHs. In contrast to other NAD-dependent dehydrogenases
there are few interactions between the negative phosphates and
the protein residues, especially due to lacking lysines or arginines
in the pocket. Instead, the interactions occur with a patch of
strong negative electrostatic potential near the phosphate binding
pocket conserved in ALDH1 and ALDH2. These interactions act
like a ball and socket joint conferring flexibility within the
molecule. The rational for nicotinamide flexibility
requirements relate to the water mediated deprotonation using
Glu268 during catalysis, with the Glu268 also exhibiting disorder.
Specifically, during the hydride transfer step the side chain of
Glu268 must be tucked away from the nicotinamide ring of the
cofactor. Before deacylation of the thioester can occur, the
nicotinamide portion must at least half exit the active site to
allow for room for the water molecule to position itself near the
thioester carbon of the acyl intermediate. Flexibility and variable
conformations of both Glu268 and the nicotinamide ring are
paramount for proper dehydrogenase action by ALDH.
The specificity of the enzyme to utilise a sole cofactor is
dictated by distinct features within the cofactor-binding
FIGURE 3 | ALDH reaction mechanism highlighting the five essential steps in the catalytic scheme.
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domain. The Rossmann fold commonly contains an acidic
residue located at the end of β2, which seemingly dictates
cofactor preference. ALDH enzymes that favor the use of
NADP may possess positively charged amino acids that
stabilise the negative 2′ phosphate moiety. Absence of an
acidic residue may prove essential for preference of NADP, as
if present, repulsion effects would occur between the two negative
charges (Perozich et al., 2000). The presence of an acidic residue
in close proximity to the position of 2′ phosphate may dictate the
cofactor specificity as it does not allow NADP to be stable within
the active site, deeming the enzyme preferable to NAD (Sharkey
et al., 2013). From structural analysis, human ALDH2 and ALDH
from Thermus thermophilus (TtALDH530) both possess a
glutamic acid residue in close proximity to the 2’ phosphate
when using NADP, while both enzymes prefer NAD. ALDH from
Vibrio Harveyi and Pyrobaculum sp. both lack a Glu residue, with
V. Harveyi possessing an adjacent lysine residue, both utilise
NADP preferably (Figure 4C). In contrast human ALDH3A1
and ALDH3A2 can use NADP but are not obligatory NADP
enzymes. They are shown to possess the corresponding acidic,
glutamate residue at the correct position despite their use of
NADP as a cofactor (Sharkey et al., 2013) (Figure 4D).
Structural Analysis of Oligomerization
State: Dimer vs. Tetramer vs. Hexamer
As previously stated ALDHs exist in dimeric or tetrameric state,
but a small number of resolved structures have now demonstrated
the presence of hexameric enzymes. ALDHs are constructed by
domain swapped dimerization with tetramers typically being
formed by a dimer-of-dimers (Figure 1). A resounding
question within the literature asks, what dictates the
oligomeric state which an ALDH enzyme adopts? In dimeric
ALDHs, an extension of approximately 17 amino acids at the
C-terminus in the form of a tail occurs. When compared to their
tetrameric counterparts a 56 amino acid deletion at the
N-terminus is present (Figures 5A,B, 6A). It has been tacitly
assumed that the presence or absence of a C-terminal tail within
FIGURE 4 | Cofactor binding mechanism of ALDH. (A) Depiction of αA and β1 of the Rossmann fold in the cofactor binding domain. (B) Varying conformations of
the nicotinamide portion and constant orientation of adenine ring of NAD demonstrated on sheep ALDH1 and bovine ALDH2 (PDB: 1BXS and 1A4Z). ALDH1 (dark gray)
and ALDH2 (light gray) are modeled as an overlay with NAD in yellow and blue, respectively. Measurements demonstrate an approximate 5 Å shift of the nicotinamide
portion. Key cofactor binding residues are highlighted in red. Residues 241–253 have been omitted for visualisation purposes. (C) NADP 2′phophate shown in
close proximity to Lys171, His173, and Arg209, no acidic residue is present in the NADP dependent ALDH from V. Harvei (PDB: 1EYY). (D) Human ALDH3A1 (PDB:
4L2O), a non-obligatory NADP ALDH, shows a NAD cofactor in close proximity to Glu139 even though this ALDH can utilise NADP.
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the enzyme dictates the oligomeric mode, between a dimer or a
tetramer. Indeed, in the dimeric structures the C-terminal tail
extends into the region where a second dimer pair would
assemble and, thus, disrupting tetramer formation (Hurley
et al., 1999; Rodriguez-Zavala and Weiner, 2001). Figure 5D
demonstrates the position of the dimeric ALDH3 C-terminal tail
FIGURE 5 | Structural features of dimeric and tetrameric ALDHs. (A) The C-terminal tail extension of dimeric ALDHs is represented in green against the monomer of
ALDH3A1 (Red, PDB: 3SZA). Note the deletion of the first 56 amino acids in comparison to image (B) of the tetrameric ALDH2 (cyan). (B) The “so-called”N-terminal extension
is represented in cyan against the monomer of ALDH2 (Blue, PDB: 1NZX). Note the absence of the C-terminal extended tail. (C) LsALDH16 monomer highlighting the NAD
binding domain (orange), the catalytic domain (red) and an extra structural domain (green). (D) Surface representation of the dimeric ALDH3A1 (light blue, PDB: 3SZA)
superimposed on ALDH2 (Gray, PDB: 1NZX). The C-terminal tail of ALDH3A1 is depicted in red. For clarity, only the opposing dimer of ALDH2 is shown.
FIGURE 6 |Graphical representation of the architecture of ALDHs. (A) ALDH class 1 and 2 being defined by a set of N-terminal residues (yellow) and the lack of the
C-terminal tail (green). ALDH class 3 being defined by the absence of N-terminal residues and presence of the C-terminal extension. Note that the TtALDH530 contains
both this N-terminal segment and the extended C-terminus with LsALDH16 containing a C-terminus constructed by a non-functional Rossmann fold domain. Modified
from Hayes, et al. (Hayes et al., 2018). (B) Representation of ALDH functional domains on a typical ALDH and AdhE spirosome of 3 subunits. Note: size of the
graphic representation does not directly relate to the size of the domains.
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in comparison to a tetrameric ALDH2 organisation. Here it is
demonstrated that the orientation of the tail is modeled toward a
region to the outer sides of the dimer. Studies which eliminated
the C-terminal tail from the dimeric structure demonstrated that
a tetramer was formed at low salt conditions but reverted back to
a dimer upon increase of ionic strength (Rodriguez-Zavala and
Weiner, 2001). Also, the addition of 5 and 17 amino acids at the
C-terminus of a tetrameric isozyme subunit was trialled, but
conversion to a dimer was not achievable. When 5 residues were
added, tetrameric structure was conserved but activity was
reduced to 30% compared to wild type. When 17 residues
were added this greatly decreased the stability of the enzyme
(Rodriguez-Zavala and Weiner, 2001). This demonstrates that
the C-terminal tail contributes to quaternary arrangement in
dimeric structures but does not affect tetrameric ones. However,
the tail is not the sole factor holding the dimer together, as upon
removal and high ionic strength the dimer was conserved,
suggesting other favourable interactions such as between single
residues or inter-domain interactions.
Until recently all tetrameric ALDHs were organized as
dimer of dimers free of C-terminal extensions. However,
emerging research suggests the contrary. The novel ALDH
from T. thermophilus HB27 (TtALDH530) Hayes et al. (2018)
showed an interesting feature with an unusual extended
C-terminal tail compared to available structures
(Figure 7). In contrast to other ALDHs, this extended tail
contributes to the tetrameric assembly and the stability of the
protein as it completely wraps the opposing monomer. This
results in the formation of a network of salt bridges and
hydrogen bonds with the N-terminal residues and
oligomerization domain of the opposite monomer. As the
tail wraps the opposing monomer, it is dragged across the
opening of the substrate entry tunnel conferring possible
roles in active site regulation. In addition, an ALDH from
Pseudomonas putida (PpALDH) contains an extension in its
oligomerization domain associated with “hugging” its
neighboring monomer and interacting with its active site
(Crabo et al., 2017). This enzyme contains an additional 6
residues in comparison to its closest related homolog, the
sheep liver ALDH1, and is associated with occluding active
site entrance perhaps conferring substrate specificity. This
enzyme ultimately preferred smaller aldehyde substrates.
Similarly, the recently resolved structure of an ALDH16
from Loktanella sp. (LsALDH16) demonstrated a unique
oligomerization mode and potential regulation of catalysis
utilising a C-terminal extension (Liu and Tanner, 2019).
ALDH16 shows what has been described as
transhierarchical structural similarity, where tertiary
interactions within one protein mimic quarternary
interactions in another. Indeed, ALDH16 features the
classical NAD and catalytic domains in addition to a large
non-functional cofactor binding domain in the C-terminal
(Figures 5C, 6A). In this case the overall structure of
LsALDH16 mimics the classical tetrameric organisation,
although being formed by only two subunits.
The first description of a membrane associated ALDH, the
dimeric fatty aldehyde dehydrogenase (FALDH), displayed an
unrecognised C-terminal, hydrophobic “gatekeeper” helix with
a function in active site restriction and substrate specificity
(Keller et al., 2014). The helix induces a 93° kink toward the SEC.
Adjacent is a transmembrane helix which typically anchors the
FALDH to the endoplasmic reticulum or peroxisomes assisting
in processing of long chain aldehydes generated in the
membrane which are not accessible to cytosolic enzymes.
Once the FALDH is embedded in the membrane the active
site funnel and “gatekeepers” are oriented toward the
membrane, with the cofactor domain toward the cytosol.
“Gatekeeper” residues form a hydrophobic ring around the
entrance to the SEC, possibly allowing for entry or fusion
with membranes to facilitate efficient substrate binding.
Removal of the gatekeeper helix resulted in reduced capacity
for hexadecanal but not toward shorter aldehydes such as
octanal (Keller et al., 2014). Recently a similar C-terminal
“gatekeeper” was observed in the Staphlococcus aureus ALDH
(SaALDH) but with the characteristic kink orientating the helix
away from the SEC (Tao et al., 2020). Upon binding of substrate
a conformational change associated with the C-helix is adopted,
a change in direction of the kink by 10.6° now orients the
“gatekeeper” toward the SEC. Without substrate, in SaALDH,
the C-helix takes an open conformation allowing for substrates
FIGURE 7 |Monomeric and tetrameric structure of TtALDH530 (PDB: 6FJX). (A)Monomer highlighting the C-terminal extension in blue. (B) Surface representation
of the tetrameric assembly, note how the C-terminal tail from one monomer wraps its diagonal monomer and interacts with its N-terminus. Monomers are represented in
contrasting colors.
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to enter, whereas with bound substrate the C-helix locks the
aldehyde in place and adopts a closed conformation.
A third oligomeric state of ALDHs exists in the form of a
hexamer (Figure 8), organized as trimer of dimers. However, this
is a less common state and there are only two resolved structures
from S. cerevisiae (ScALDH4A1, 4OE6) and T. thermophilus
(TtP5CDH, pyrroline-5-carboxylate dehydrogenase, 2BHQ),
with another unavailable structure from Deinococcus
radiodurans being reported (Inagaki et al., 2006; Luo et al.,
2013; Pemberton et al., 2014). No mammalian hexameric
structures have been reported to date. Work on TtP5CDH
showed that the formation of the hexamer is mainly associated
with the presence of a hexamerization hotspot. An arginine
residue was identified in the bacterial model while a
tryptophan residue assumes this role in ScALDH4A1
(Pemberton et al., 2014). Without this essential hotspot
residue, hexamer formation is compromised (Luo et al., 2013).
Interestingly, through our own structural analysis, a unique
feature of the hexamer structure was identified. In TtP5CDH,
a 33 amino acid extension of the N-terminus is evident, consisting
of a loop of 15 amino acids penetrating the pore formed by the
hexameric assembly and interacting with the adjacent subunit,
while the remaining 18 residues are organized in an alpha helix.
In comparison, the yeast ScALDH4A1 shows a similar alpha
helix, however, with the first 30 amino acids not visible in the
structure due to disorder (Figure 8).
Alcohol Dehydrogenase-Aldehyde
Dehydrogenase Bifunctional Spirosomes
Aldehyde-alcohol dehydrogenase (AdhE) is a bifunctional
enzyme, key to bacterial metabolic processes in physiology and
pathology, which contains two enzyme domains, ALDH and
alcohol dehydrogenase (ADH). While monofunctional ALDH
and ADH are found in all kingdoms of life, AdhE is mostly found
in bacteria and some unicellular eukaryotes such as microalgae.
These helical macromolecule assemblies, called spirosomes, were
first discovered in 1975 Kawata et al. (1975) and were more
recently designated as filaments (Pony et al., 2020). A recent, in
depth study of the E. coli AdhE was carried out by Kim et al.
highlighting their critical structure-function relationship (Kim
et al., 2019). The AdhE monomer (96.1 kDa) is composed of an
ALDH and ADH domain separated by a linker of 7 amino acid
residues (Figure 6B). Together with the protruding β-turn from
the ALDH domain the linker forms a 3 stranded β-sheet for
connection of the two catalytic domains. The structures of the
ALDH and ADH domains are similar to other known structures,
both contain two lobes, the ALDH with a Rossmann fold and
NADH binding cleft, while the ADH contains an Fe2+ and
NADH binding pocket. Two AdhE monomers form a dimer
in a head-to-head arm crossing fashion. To then form the
spirosome structure, dimers are almost stacked one on top of
each other, through use of hydrophobic interactions mediated by
the ADH domains. For example, six AdhE molecules with two
ADH domains at either end will consist of approximately 1.5
helical turns. Repetition of the helical unit leads to spirosome
formation (Figure 9).
It is determined that the spirosome structure is crucial to
maintain catalytic activity of the AdhE, with the ALDH and ADH
activity topologically separated due to the helical filamentous
structure (Kim et al., 2019). Within the structure, the ALDH and
ADH domains from different subunits are clustered together
rather than intertwined with mismatching domains. This allows
for dividing of activity and the ability for the ALDH and ADH to
work solely and more efficiently. The ALDH active site is located
toward the outer surface of the helical structure, while the ADH
FIGURE 8 | ALDH hexameric structure (A) Superimposition of the monomers of yeast ALDH4A1 (orange) and TtP5CDH (green) (PDB: 4OE6, 2BHQ, respectively),
demonstrating the N-terminal extension equipped with an alpha helix in hexamer forming ALDHs. Extension is shown in red for TtP5CDH and yellow for yeast. (B) The
hexameric assembly of TtP5CDH (PDB: 2BHQ) with the N-terminal loop (red) penetrating the pore formed by the hexamer.
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active site resides toward the inner surface. Effective elimination
of cytotoxic acetaldehyde is imagined. The acetaldehyde
produced by ALDH will not enter the cell, it will be passed to
the ADH within the spirosome structure for timely conversion to
ethanol. Additionally, maintenance of the spirosome structure
proved critical in AdhE catalytic activity. Disruption of spirosome
formation and generation of free dimers through mutation led to
a dramatic decrease in AdhE activity. It is notable that spirosome
formation proved critical for maintenance of the forward ALDH
reaction, conversion of Acetyl Co A to acetaldehyde, but no other
reactions, suggesting that the spirosome might play a role in
regulating the direction of AdhE activity.
The outer residing ALDH of the AdhE is exposed to solvent,
whereas the ADH on the inside of the compact spirosome is not
readily accessible. AdhE spirosomes undergo a structural
transition in the presence of cofactor to assist with catalysis
(Kim et al., 2020). A compact form is changed into an
elongated, extended spirosome upon addition of cofactor
(Kessler et al., 1991; Kim et al., 2019). Further suggestions lead
to the cofactor binding in the ADH domain being the most
critical to initiate the change. This transition may be involved in
regulation of AdhE activity. Substantial structural changes upon
binding of the cofactor leads to a widely opened spirosome with
an accessible ADH catalytic pocket. Moreover, the transition
creates a substrate channel between the ALDH and ADH active
sites, from two different subunits, which is accessible to solvent
and thus substrates and products (Kim et al., 2020). In this
conformation the otherwise restricted ADH active site is
accessible to solvent from both outside and inside, with the
inter-domain channel likely playing a role for transition of
intermediate products, assisting with the bifunctional cascade




ALDH enzymes are diverse in their function across all kingdoms
of life, contributing to detoxification Esterbauer et al. (1991),
Kelson et al. (1997), Choudhary et al. (2005), Ho and Weiner
(2005), Rodríguez-Zavala et al. (2006), Marchitti et al. (2007),
Shin et al. (2009), Jackson et al. (2011), Ouyang et al. (2020),
biosynthesis Yoshida et al. (1992), Mellema et al. (2002), Kim
et al. (2015), Pequerul et al. (2020), and non-enzymatic functions
such as anti-oxidant Estey et al. (2007), Lassen et al. (2008),
Marchitti et al. (2011), Singh et al. (2013), Voulgaridou et al.
(2020), structural Piatigorsky (1998), Voulgaridou et al. (2017)
and regulatory mechanisms Moreb (2008), Vassalli (2019),
Voulgaridou et al. (2020) (Table 1). Proper function of these
enzymes is essential for maintenance of cell function and survival,
with prominent ALDH-linked diseases arising from mutation,
catalytic knockout and structural disruption. Knowledge of the
molecular and structural basis for diseases is critical for
understanding pathology and ultimately for therapeutic design,
typically via comparison of wild type andmutants. However, with
regards to ALDH disease in literature, focus is mainly upon
phenotype and not enzyme structure. A detailed breakdown of
human ALDH related disease is shown in Table 2 (Chao et al.,
1994; Dupé et al., 2003; Deak et al., 2005; Hui et al., 2007; Jo et al.,
2007; Lassen et al., 2007; Husemoen et al., 2008; Marchitti et al.,
2008; Pavan et al., 2009; Guo et al., 2010; Palo et al., 2010;
Palmfeldt et al., 2011; Sulem et al., 2011; Sass et al., 2012; Vasiliou
et al., 2013). Herein, we summarise and discuss previously studied
ALDH diseases in context of mutations and their effect on ALDH
structure and function. Disease causing mutations present in the
ALDH superfamily can be arranged into three groups, these will
be designated for the purpose of this review as 1) those that affect
NAD binding, 2) those that affect the substrate binding site and 3)
those that disrupt quarternary structure formation.
ALDH2. The mitochondrial ALDH2, plays a significant role
in ALDH-linked pathology and may be the most extensively
discussed ALDHwithin literature in terms of disease. Specifically,
the single nucleotide polymorphism E487K Farrés et al. (1994),
Larson et al. (2007) residing in the oligmerization domain,
FIGURE 9 | AdhE extended spirosome structure shown as a cartoon
with transparent surface representation (PBD: 7BVP). ALDH domains located
on the outer surface are shown in brown, ADH domains in blue on the inside of
the spirosome and the 7 amino acid linker between domains in red. The
dotted line demonstrates the helical axis of the spirosome.
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resulting in the ALDH2*2 variant, is related to complications in
cardiovascular disease Chen et al. (2019), cancer Seitz and Stickel
(2010), alcohol intolerance Chang et al. (2017) and late onset
Alzheimer’s disease (Kamino et al., 2000). ALDH2*2 can be
designated as group 1 and 3 in relation to structure-function
disruption. When just one protomer of the tetrameric assembly
contains ALDH2*2, NAD binding is altered and catalytic activity
is lost, resulting in accumulation of cytotoxic acetaldehyde
(Larson et al., 2005). This mutation is responsible for a 200-
fold increase in KM for NAD and a 10-fold reduction in kcat,
ultimately severely reducing catalytic rate in-vivo. Physiological
levels of NAD cannot reach the demand of the ALDH2*2. Within
ALDH2, the adenosine portion of NAD is nestled within the cleft
present between αF and αG of the Rossmann fold. The αG helix is
situated at the dimer interface and interacts with its same helix
from the opposing subunit. Glu487 forms hydrogen bonds with
Arg264 and Arg475 located on the C-terminus of α-G and within
a loop on the opposing subunit respectively. With the E487K
substitution, stabilisation of αG and the loop containing Arg475 is
lost, leading to dimer destabilisation, NAD binding site disorder
and some active site residue repositioning. Specifically, residues
Glu399 and Glu268 essential in coenzyme positioning and
catalysis respectively. A clinically relevant, specific activator of
ALDH2*2 named Alda-1, was found to enhance enzyme activity
in-vitro and in-vivo. Importantly Alda-1 restores activity lost by
the E487K mutation, through binding at the entrance of the
catalytic tunnel, dramatically decreasing KM for cofactor and
increasing Vmax (Chen et al., 2008; Perez-Miller et al., 2010).
E487K substitution in ALDH2 causes a loss of electron density at
helix αG, and active site loop containing Arg475. As revealed by
the crystal structure of Alda-1 in complex with ALDH2*2,
binding of Alda-1 restores the αG structure and the loop even
though Alda-1 has no direct contact with these residues (Perez-
Miller et al., 2010). Alda-1 is therefore an agonist and
simultaneously functions as a chemical chaperone, exerting
allosteric effect to restore the structural defect of a catalytically
impaired enzyme (C.-H. Chen et al., 2014).
ALDH7A1. ALDH7A1 is responsible for lysine catabolism
and its improper function is related to a seizure causing disorder
named pyridoxine-related epilepsy (PDE), linked with approx. 60
missense mutations Stenson et al. (2008); van Karnebeek et al.
(2016), Coughlin et al. (2018) which are highly considered within
the literature. Interestingly, the classification of the mutations led
to different symptom severity and treatment options in patients.
Group 1 allowed for complete seizure control and normal
developmental outcome, group 2 complete seizure control but
TABLE 1 | ALDH function, categorically highlighting examples of contribution to specific mechanisms.
Biological Function Examples
Catalytic Detoxification Removal of aldehydes, e.g., acetaldehyde, fatty aldehydes
Fucose and phenylalanine metabolism in E. coli
Biosynthesis Retinoic acid synthesis in humans
γ-aminobutyric acid synthesis in humans
Osmoprotection by synthesis of betaine in prokaryotes
Non-Catalytic Anti-oxidant Indirect NAD(P)H generation
UV absorption in the eye
Structural Corneal and lens crystallins
Regulatory Biomarkers and regulators of stem cells
γ-aminobutyric acid synthesis pathway regulation
Regulation of osmotic pressure
Regulation of genes by retinoic acid
Binding Binding of endobiotics and xenobiotics
Androgen, thyroid hormone and cholesterol binding
TABLE 2 | Human diseases linked to ALDH genes.
Gene Disease
Aldh1a1 Cataract formation; Parkinson’s disease
Aldh1a2 Disrupted embryonic development; spina bifida; rare cases of congenital heart disease
Aldh1a3 Disrupted embryonic development
Aldh1b1 Hypertension; ethanol sensitivity; ethylmalonic encephalopathy; bipolar disorder
Aldh2 Alcohol intolerance; heart attack; hypertension; cancers; liver cirrhosis; Parkinson’s and late onset Alzheimer’s disease
Aldh3a1 Cataract formation
Aldh3a2 Sjogren-Larsson syndrome
Aldh4a1 Type II hyperprolinemia
Aldh5a1 γ-hydroxybutyric aciduria
Aldh6a1 Psychomotor delay; methylmalonic aciduria
Aldh7a1 Pyridoxine-dependent epilepsy; osteoporosis
Aldh16a1 Gout
Aldh18a1 Hyperammonemia
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developmental delay and group 3 showed persistent seizures with
developmental delay. This suggests that multimer disruption is
most detrimental in terms of ALDH7A1 dysfunction.Many of the
associated mutations are surface accessible suggesting a role in
retention of tetrameric assembly (Scharer et al., 2010). A study
investigating 6 mutations (A129P, G137V, G138V, A149E,
G255D, G236E) on ALDH7A1 present at the tetrameric
interface and remote from the active Cys (18–28 Å) abolished
enzyme activity indirectly and disrupted tetramer formation
(Korasick et al., 2017). The most common missense mutation
in ALDH7A1 has been reported as E427G Coughlin et al. (2018),
occurring in 30% of PDE patients Mills et al. (2006), Plecko et al.
(2007), Mills et al. (2010), a mutational hotspot for disease. A
study investigating structural changes of ALDH7A1, exhibiting
mutations E427G, E427Q and E427D, demonstrated a catalytic
defect and a non-natural conformation of the NAD cofactor and
as a result no catalytic activity (Laciak et al., 2020). The NAD
adopts a flexible conformation and lacks a defined pose for E427G
and E427Q variants whereas an inactive pose is demonstrated for
E427D, compromising catalysis due to lack of stabilisation and
increased distance of the cofactor from active site Cys. In
addition, this study again demonstrates the criticality of
oligomerization for correct function with all three mutant
variants compromised in tetramer assembly.
FALDH/ALDH3A2. ALDH3A2 is an endoplasmic reticulum
bound FALDH responsible for the conversion of fatty aldehydes
to fatty acids. Sjogren Larsson syndrome is a genetic disorder
characterised by scaling skin, speech abnormalities, intellectual
disability and spasticity caused by an autosomal recessive
mutation in ALDH3A2, resulting in accumulation of
aldehydes (Cho et al., 2018). Catalytic site mutations are
mostly found in exon 4 with most exons harboring protein
misfolding mutations. Interestingly the most frequent
mutations, totalling 16, occur in exon 9, relating to coding
for the C-terminal “gatekeeper” helix. As previously
mentioned this “gatekeeper” assists in selection and easy
processing of medium to long fatty aldehydes. Realised
pathology could be associated with alterations in this helix as
it may cause a shift in substrate specificity, inhibiting the removal
of fatty aldehydes from the cell.
CONCLUDING REMARKS
The ongoing ALDH structure-function investigation is important
for elucidating the novel features of these enzymes as well as the
underlying mechanism for the cause of many diseases.
Advancement in recent years lead to the understanding of new
oligomerization modes, domains, extensions and bifunctionality
contributing to both structure and function. The evolutionary
progress of these enzymes clearly shows their adaptation for
tailoring of the enzyme structure for processing of defined
substrates: spirosomes for efficient shuttling of substrates
between two enzyme domains within one structure conferring
reduced cytoxicity, hydrophobic helices for selection of fatty
aldehydes as well as membrane anchorage and appropriate
geometry of the SEC for processing of the correct sized
aldehyde. Vast fundamental knowledge of the ALDH has been
paramount for the understanding of pathological diseases caused
by ALDH. Deep understanding of human ALDH catalytic
mechanisms, cofactor binding and geometry of the active site
and SEC has allowed for in some cases complete characterisation
of disease models in terms of diagnosis, development,
biochemistry and even ALDH structural mechanisms. As an
ever growing superfamily of enzymes, new characteristic
features will develop over time, particularly in the area of
prokaryotic models. This will lead to shaping of an already
well-defined family of enzymes, however adding insights and
interpretation. While all members generally follow the common
ALDH architecture, it is now the smaller, more niche aspects
which help us develop the key understanding of these enzymes,
ultimately to pick apart ALDH structure, function and disease
models in a profound manner.
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